Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: LXH254
DRUG: LTT462
DRUG: Trametinib
DRUG: Ribociclib

Sponsor

Novartis Pharmaceuticals